All News

Exercise may help prevent cancer or its recurrence and improve quality of life for survivors of the disease.

Treatment with a novel immuno-oncology therapy demonstrated a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

Cancer loves glucose, which is why fasting, restricting calorie consumption or following the ketogenic diet may make chemotherapy and some other cancer treatments more effective and easier to tolerate, early evidence shows.

Taking cholesterol-lowering drugs may provide a mortality benefit in women with newly diagnosed colorectal cancer, breast cancer and melanoma, although more research is needed to confirm this potential association.

From Nov. 1-Dec. 15, consumers can shop for health plans offered under the Affordable Care Act. One advocate suggests that all patients compare policies to ensure the best fit for their particular needs and budget.

Results of this trial led to an accelerated FDA approval of Opdivo (nivolumab) and Yervoy (ipilimumab) in March to treat this specific patient population.

On social media, CURE® recently asked its readers to give a shout out to their ‘cancer hero’: the person or persons who they met while on their cancer journey and they now admire.

Each month, we take a look back at the most popular CURE® stories. Here are the top five for October 2020.

One patient shares their story of how her oncology nurse changed her cancer journey by being there with her every step of the way.

Oncology nurses have a special understanding of their patients and their patients' needs. One patient shares their story on how that special understanding made a major difference in her cancer journey.

Twelve works will be selected to appear in a 2021 CURE® calendar, and all submissions will be displayed in the magazine’s online art gallery.

A breast surgical oncologist at The University of Texas MD Anderson Cancer Center notes that while breast cancer screening can be delayed a few months, it should not be skipped altogether.

Two sisters diagnosed with the same stage of breast cancer in the same spot three weeks apart take part in proton therapy trial, Mayo Clinic and Google Health partner to investigate the use of artificial intelligence in assisting with radiotherapy treatments and more from the weekly roundup of news and research happening in the cancer landscape.

Ultra-precise drug targeting brings new hope for patients with non-small cell lung cancer that harbors rare mutations.

Giving fewer courses of chemotherapy and no radiation could become a new standard for patients with stage 1 or 2 diffuse large B cell lymphoma based on the results of a recent study.

Here is a list of some recent trials that launched within the cancer space in October.

As colorectal cancer is becoming more prevalent in younger patients, the U.S. Preventive Services Task Force (USPSTF) introduced a draft recommendation that, if accepted, will lower the screening age from 50 years to 45 years in those with average risk.

5-year follow up data from a promising trial shows survival benefits with the combination treatment of Tafinlar and Mekinist with patients with melanoma.

A study assessing the value of movement found that it improved physical and mental health in older adults who had survived cancer, as well as those with no history of the disease.

A liquid biopsy may soon be available to find early signs of cancer in asymptomatic patients when the disease is still treatable and even curable.

A roundup of the latest news and updates for patients with breast cancer from CURE®.

In addition to showing clinically meaningful, durable responses, Tazverik (tazemetostat) was generally well-tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to the results of an open-label, single-arm, multicenter phase 2 study.

Justice Amy Coney Barrett was sworn in to the Supreme Court on Tuesday. Her vote would be instrumental in deciding the fate of the Affordable Care Act. If it’s repealed during November’s landmark case, many could lose access to cancer screening and treatment.

The FDA granted a priority review to the biologics license application and new drug application for the combination of Opdivo and Cabometyx for patients with advanced kidney cancer.

A roundup of the latest news and updates for patients with myeloma from CURE®.

A meta-analysis of six clinical trials showed that standard treatment regimens for high-risk multiple myeloma may be more effective at delaying disease progression if they are given in combination with the targeted drug Darzalex (daratumumab).

The dependent coverage provision in the Affordable Care Act has helped adolescent and young adult patients with cancer stay on health insurance longer than those who had cancer before the ACA was signed into law.

Not everyone with myeloma needs to be treated right away, but when they do, there are some important upfront considerations for patients and providers.